Briacell Therapeutics Corp.

Biotechnology • Healthcare • West Vancouver, BC, United States • BCTXZ (NCM)

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

604 921 1810 Bellevue Centre, West Vancouver, BC V7T 2X1, Canada

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why BriaCell Therapeutics Corp. Equity Warrant stock is favored by pension funds - bollywoodhelpline.com

bollywoodhelpline.com • Dec 29

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - Investing News Network

Investing News Network • Dec 9

BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire

GlobeNewswire • Aug 21

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025 - Yahoo Finance

Yahoo Finance • Dec 10

BriaCell Subsidiary BriaPro Files Interim Financial Results - TipRanks

TipRanks • Dec 29

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has BriaCell Therapeutics Corp. had layoffs?

No layoff events have been recorded for BriaCell Therapeutics Corp. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

What industry is BriaCell Therapeutics Corp. in?

BriaCell Therapeutics Corp. operates in the Biotechnology industry, within the Healthcare sector.

Is BriaCell Therapeutics Corp. a publicly traded company?

Yes, BriaCell Therapeutics Corp. is publicly traded under the ticker symbol BCTXZ on the NCM.

Where is BriaCell Therapeutics Corp. headquartered?

BriaCell Therapeutics Corp. is headquartered in West Vancouver, BC, United States at Bellevue Centre, West Vancouver, BC V7T 2X1, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.